Document is current
Any future updates will be listed below
-
Authors
Muiruri, Charles https://orcid.org/0000-0003-0213-0362
Corneli, Amy
Cooper, Linda
Dombeck, Carrie
Gray, Shamea
Longenecker, Chris T.
Meissner, Eric G.
Okeke, Nwora Lance
Pettit, April C.
Swezey, Teresa
Vicini, Joseph
Bloomfield, Gerald S.
-
Funding
Funding for this research was provided by:
National Institute for Minority Health and Health Disparities (R01MD013493)
National Heart, Lung, and Blood Institute (U01 HL142099, K01HL159052)
National Institutes of Health (P30 AI064518, K23 HL137611, R01 MH113438, P30 AI110527)
- License Information
-
More Information
Article History
Received: 17 December 2021
Accepted: 29 April 2022
First Online: 9 May 2022
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the DUMC Institutional Review Board (IRB) as IRB of record for VUMC, CWRU, and MUSC through a single institutional review board reliance agreement.The study received waiver of informed consent from the IRB (Pro00101663) and therefore did not have verbal or written informed consent. The study qualified for Exempt Research status under 45 CFR 46.101(b)(2).
: Not Applicable.
: CTL has served on an advisory board for Esperion Therapeutics and has received research funding from Gilead Sciences. The authors report no real or perceived vested interests related to this article that could be construed as a conflict of interest.
